Topic chronic myeloid leukemia

Novartis has received a positive opinion recommending European Union approval of Tasigna® (nilotinib), a selective targeted therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The Committee for Medicinal Products for more

Swissmedic has granted approval for Tasigna® (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna is the first new therapeutic option for newly diagnosed patients since th more

Following a priority review, the US Food and Drug Administration (FDA) has approved Tasigna® (nilotinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. With this approval, Tasigna becomes the first new th more

Motivation: Selecting a small number of signature genes for accurate classification of samples is essential for the development of diagnostic tests. However, many genes are highly correlated in gene expression data, and hence, many possible sets of genes are potential classifiers. Because treatment more

Purpose We investigated the population pharmacokinetics and exposure-response relationship of nilotinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase. Methods Nilotinib was given at 300 mg or 400 mg twice daily. Serum concentration data (sparse and full pharmacokin more

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia Leukemia 25, 1433 (September 2011). doi:10.1038/leu.2011.116 Authors: M Pfirrmann, A Hochhaus, M Lauseker, S Saußele, R Hehlmann more

Introduction Global Markets Direct’s, 'Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2012', provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutic pipeline. This report provides information on the therapeutic developm more

BMI View: While South Korea's research and development (R&D) environment may be attractive to investors, its pharmaceutical market environment is rather uncertain given the dispute between pharmaceutical companies and the government over pharmaceutical price cuts. We hold to our view that, if the go more